 |
인쇄하기
취소
|
Hanmi, Spectrum enter agreement over neutropenia treatment
Hanmi Pharmaceutical said Tuesday that it has signed a co-development and commercialization Agreement with the US based Spectrum Pharmaceuticals on Hanmi’s new biopharmaceutical LAPS-GCSF (HM10460A/neutropenia drug).
LAPS-GCSF is a Biobetter product that utilizes Hanmi's proprietary platform technology LAPSCOVERY. This enables less dosing frequency (once every 3 weeks) and less dosage in pa...
LAPS-GCSF is a Biobetter product that utilizes Hanmi's proprietary platform technology LAPSCOVERY. This enables less dosing frequency (once every 3 weeks) and less dosage in pa...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.